Moderna Inc. reported that it will ask U.S. and European regulators on Monday to grant emergency use of its COVID-19 vaccine as the latest study revealed that their shots offered strong protection — ramping up the race to begin limited vaccinations as the coronavirus rampage worsens.
Moderna is just behind Pfizer and its German partner BioNTech is asking authorities to use vaccinations in the U.S. in December. British regulators are assessing the shots from Pfizer and another from AstraZeneca.
Moderna created its shots with the U.S. National Institutes of Health and gave us a hint that they are working together and suggested that their vaccine is more than 94% effective.
Of 196 COVID-19 cases so far in its huge U.S. study, 185 were trial participants who received the placebo and 11 who got the real vaccine. The only people who got severely ill — 30 participants, including one who died — had received dummy shots, said Dr. Tal Zaks, the Cambridge, Massachusetts, company's chief medical officer.